1. Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Kawahara T, Ohashi Y, Mukai H (2020) Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. J Clin Oncol 38:3743-3752. doi: 10.1200/jco.20.00184
2. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145. doi: 10.1200/JCO.2006.09.2775
3. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570-579. doi: 10.1200/jco.1993.11.3.570
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672. doi: 353/16/1659 [pii] 10.1056/NEJMoa052306
5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684. doi: 353/16/1673 [pii] 10.1056/NEJMoa052122
6. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet 369:29-36. doi: 10.1016/s0140-6736(07)60028-2
7. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283. doi: 10.1056/NEJMoa0910383
8. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32. doi: 10.1016/s1470-2045(11)70336-9
9. Nguy S, Wu SP, Oh C, Gerber NK (2021) Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy. Breast Cancer Res Treat 187:815-830. doi: 10.1007/s10549-021-06115-9
10. Dall P, Koch T, Gohler T, Selbach J, Ammon A, Eggert J, Gazawi N, Rezek D, Wischnik A, Hielscher C, Schleif N, Cirrincione U, Hinke A, Feisel-Schwickardi G (2018) Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study. BMC Cancer 18:51. doi: 10.1186/s12885-017-3857-5
11. Davis S, Wright PW, Schulman SF, Hill LD, Pinkham RD, Johnson LP, Jones TW, Kellogg HB, Jr., Radke HM, Sikkema WW, et al. (1985) Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 56:1710-1718. doi: 10.1002/1097-0142(19851001)56:7<1710::aid-cncr2820560741>3.0.co;2-t
12. Udell JA, Wang TY, Li S, Kohli P, Roe MT, de Lemos JA, Wiviott SD (2014) Clinical trial participation after myocardial infarction in a national cardiovascular data registry. JAMA 312:841-843. doi: 10.1001/jama.2014.6217
13. Ohno S, Mukai H, Narui K, Hozumi Y, Miyoshi Y, Yoshino H, Doihara H, Suto A, Tamura M, Morimoto T, Zaha H, Chishima T, Nishimura R, Ishikawa T, Uemura Y, Ohashi Y (2019) Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. Breast Cancer Res Treat 176:631-635. doi: 10.1007/s10549-019-05276-y
14. Tanai C, Nokihara H, Yamamoto S, Kunitoh H, Yamamoto N, Sekine I, Ohe Y, Tamura T (2009) Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials. Br J Cancer 100:1037-1042. doi: 10.1038/sj.bjc.6604982
15. Keizman D, Rouvinov K, Sella A, Gottfried M, Maimon N, Kim JJ, Eisenberger MA, Sinibaldi V, Peer A, Carducci MA, Mermershtain W, Leibowitz-Amit R, Weitzen R, Berger R (2016) Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? Cancer Res Treat 48:281-287. doi: 10.4143/crt.2014.289
16. Peppercorn JM, Weeks JC, Cook EF, Joffe S (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. The Lancet 363:263-270. doi: 10.1016/s0140-6736(03)15383-4
17. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815. doi: 10.1200/JCO.2006.10.4976
18. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH (2007) Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk. J Clin Oncol 25:3871-3876. doi: 10.1200/jco.2007.12.0832
19. Du XL, Xia R, Liu CC, Cormier JN, Xing Y, Hardy D, Chan W, Burau K (2009) Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer 115:5296-5308. doi: 10.1002/cncr.24621 [doi]
20. Dall P, Lenzen G, Gohler T, Lerchenmuller C, Feisel-Schwickardi G, Koch T, Eggert J, Heilmann V, Schindler C, Wilke J, Tesch H, Selbach J, Wohlfarth T, Eustermann H, Hinke A (2015) Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany. J Geriatr Oncol 6:462-469. doi: 10.1016/j.jgo.2015.06.003
21. Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 32:927-934. doi: 10.1200/JCO.2013.51.1261
22. Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A (2013) Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev 39:44-50. doi: 10.1016/j.ctrv.2012.03.009
23. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055-2065. doi: 10.1056/NEJMoa0810266
24. Kornblith AB, Lan L, Archer L, Partridge A, Kimmick G, Hudis C, Winer E, Casey R, Bennett S, Cohen HJ, Muss HB (2011) Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907. J Clin Oncol 29:1022-1028. doi: 10.1200/jco.2010.29.9859
25. Taira N, Sawaki M, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Ohashi Y, Mukai H, Kawahara T (2021) Health-related quality of life with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as adjuvant therapy in older patients with HER2-positive breast cancer. J Clin Oncol 20.02751, in press.
26. Hagiwara Y, Sawaki M, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Takahashi M, Saito T, Baba S, Kobayashi K, Mukai H, Taira N (2021) Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial. Breast Cancer Res Treat 188:675-683. doi: 10.1007/s10549-021-06253-0
27. Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, Feng T, Smith D, Sun CL, De Glas N, Cohen HJ, Katheria V, Doan C, Zavala L, Levi A, Akiba C, Tew WP (2016) Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. J Clin Oncol 34:2366-2371. doi: 10.1200/JCO.2015.65.4327
28. Magnuson A, Sedrak MS, Gross CP, Tew WP, Klepin HD, Wildes TM, Muss HB, Dotan E, Freedman RA, O'Connor T, Dale W, Cohen HJ, Katheria V, Arsenyan A, Levi A, Kim H, Mohile S, Hurria A, Sun CL (2021) Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. J Clin Oncol 39:608-618. doi: 10.1200/jco.20.02063
29. Leonard R, Ballinger R, Cameron D, Ellis P, Fallowfield L, Gosney M, Johnson L, Kilburn LS, Makris A, Mansi J, Reed M, Ring A, Robinson A, Simmonds P, Thomas G, Bliss JM (2011) Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase? Br J Cancer 105:1260-1266. doi: 10.1038/bjc.2011.377